The Food and Drug Administration will allow a new device to be marketed as a treatment for dry age-related macular degeneration.
Instead of consistently stepping up the dose to a target dose of 2.4 mg as the manufacturer’s instructions and ... Perhaps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback